VolitionRx (VNRX) Competitors $0.68 -0.04 (-5.56%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends VNRX vs. BMEA, LXEO, ADCT, TCRX, PYXS, LFCR, ACRV, ZURA, SOPH, and MGNXShould you be buying VolitionRx stock or one of its competitors? The main competitors of VolitionRx include Biomea Fusion (BMEA), Lexeo Therapeutics (LXEO), ADC Therapeutics (ADCT), TScan Therapeutics (TCRX), Pyxis Oncology (PYXS), Lifecore Biomedical (LFCR), Acrivon Therapeutics (ACRV), Zura Bio (ZURA), SOPHiA GENETICS (SOPH), and MacroGenics (MGNX). These companies are all part of the "pharmaceutical products" industry. VolitionRx vs. Biomea Fusion Lexeo Therapeutics ADC Therapeutics TScan Therapeutics Pyxis Oncology Lifecore Biomedical Acrivon Therapeutics Zura Bio SOPHiA GENETICS MacroGenics Biomea Fusion (NASDAQ:BMEA) and VolitionRx (NYSE:VNRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, community ranking, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment. Which has preferable earnings & valuation, BMEA or VNRX? VolitionRx has higher revenue and earnings than Biomea Fusion. VolitionRx is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiomea FusionN/AN/A-$117.25M-$4.01-1.63VolitionRx$770K81.84-$35.32M-$0.36-1.89 Is BMEA or VNRX more profitable? Biomea Fusion has a net margin of 0.00% compared to VolitionRx's net margin of -3,318.42%. VolitionRx's return on equity of 0.00% beat Biomea Fusion's return on equity.Company Net Margins Return on Equity Return on Assets Biomea FusionN/A -118.90% -93.66% VolitionRx -3,318.42%N/A -165.21% Does the media refer more to BMEA or VNRX? In the previous week, VolitionRx had 3 more articles in the media than Biomea Fusion. MarketBeat recorded 5 mentions for VolitionRx and 2 mentions for Biomea Fusion. Biomea Fusion's average media sentiment score of 0.71 beat VolitionRx's score of 0.53 indicating that Biomea Fusion is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biomea Fusion 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive VolitionRx 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in BMEA or VNRX? Biomea Fusion received 46 more outperform votes than VolitionRx when rated by MarketBeat users. Likewise, 65.79% of users gave Biomea Fusion an outperform vote while only 10.81% of users gave VolitionRx an outperform vote. CompanyUnderperformOutperformBiomea FusionOutperform Votes5065.79% Underperform Votes2634.21% VolitionRxOutperform Votes410.81%Underperform Votes3389.19% Do institutionals and insiders believe in BMEA or VNRX? 96.7% of Biomea Fusion shares are owned by institutional investors. Comparatively, 8.1% of VolitionRx shares are owned by institutional investors. 27.6% of Biomea Fusion shares are owned by company insiders. Comparatively, 12.8% of VolitionRx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more risk & volatility, BMEA or VNRX? Biomea Fusion has a beta of -0.41, meaning that its share price is 141% less volatile than the S&P 500. Comparatively, VolitionRx has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500. Do analysts recommend BMEA or VNRX? Biomea Fusion currently has a consensus price target of $30.50, suggesting a potential upside of 367.08%. VolitionRx has a consensus price target of $2.50, suggesting a potential upside of 267.65%. Given Biomea Fusion's stronger consensus rating and higher probable upside, equities analysts plainly believe Biomea Fusion is more favorable than VolitionRx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biomea Fusion 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.00VolitionRx 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryBiomea Fusion beats VolitionRx on 12 of the 18 factors compared between the two stocks. Ad Weiss RatingsTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Get VolitionRx News Delivered to You Automatically Sign up to receive the latest news and ratings for VNRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VNRX vs. The Competition Export to ExcelMetricVolitionRxDiagnostic substances IndustryMedical SectorNYSE ExchangeMarket Cap$63.01M$2.19B$5.13B$19.80BDividend YieldN/A0.72%5.18%3.51%P/E Ratio-1.892.4366.7335.39Price / Sales81.8439.681,265.2917.78Price / CashN/A14.7440.2121.45Price / Book-6.182.996.454.64Net Income-$35.32M$29.98M$119.73M$982.94M7 Day Performance-1.97%-11.24%-5.13%-2.12%1 Month Performance-6.82%-12.49%-2.71%-0.39%1 Year Performance-9.08%-20.97%31.08%23.34% VolitionRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VNRXVolitionRx2.0574 of 5 stars$0.68-5.6%$2.50+267.6%-10.5%$63.01M$770,000.00-1.8980Analyst ForecastNews CoverageGap DownHigh Trading VolumeBMEABiomea Fusion3.7157 of 5 stars$7.11+0.3%N/A-30.0%$257.67MN/A-1.7750LXEOLexeo Therapeutics2.469 of 5 stars$7.78+1.8%N/A-40.0%$257.22M$650,000.00-0.5358Analyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumeADCTADC Therapeutics2.8286 of 5 stars$2.65-6.0%N/A+275.8%$256.23M$69.56M-1.11310Short Interest ↓TCRXTScan Therapeutics2.4915 of 5 stars$4.82-8.2%N/A-7.2%$255.32M$21.05M-4.55100Earnings ReportAnalyst ForecastAnalyst RevisionNews CoveragePYXSPyxis Oncology0.95 of 5 stars$4.28flatN/A+185.0%$254.32MN/A-4.1660Short Interest ↑Analyst RevisionNews CoverageLFCRLifecore Biomedical2.7141 of 5 stars$6.68-5.8%N/A-13.9%$246.02M$128.26M83.50690ACRVAcrivon Therapeutics2.9924 of 5 stars$7.92-0.1%N/A+56.8%$245.28MN/A-2.8658Analyst ForecastAnalyst RevisionNews CoverageZURAZura Bio3.9504 of 5 stars$3.60-17.8%N/A-25.8%$241.95MN/A0.003Analyst RevisionHigh Trading VolumeSOPHSOPHiA GENETICS1.8498 of 5 stars$3.70+1.4%N/A-3.6%$241.91M$62.37M-3.39520Short Interest ↑MGNXMacroGenics3.8281 of 5 stars$3.81+1.1%N/A-49.6%$239.12M$58.75M-2.41430 Related Companies and Tools Related Companies BMEA Alternatives LXEO Alternatives ADCT Alternatives TCRX Alternatives PYXS Alternatives LFCR Alternatives ACRV Alternatives ZURA Alternatives SOPH Alternatives MGNX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:VNRX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VolitionRx Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share VolitionRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
